The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

Journal of Translational Medicine

Lisong Teng⁴  Jiang Cao²  Xiangdong Wang⁵  Weizhu Wu⁶  Elena López³  Tianxiang Chen¹  Yu Gu⁴ 

[1] Department of Thoracic Surgery, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China;Clinical Research Center, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China;Hospital Universitario Niño Jesús, Av. Menéndez Pelayo 65, Madrid 28009, Spain;Department of Surgical Oncology, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, 79, Qingchun Road, Hangzhou 310003 Zhejiang Province, China;Department of Respiratory Medicine, The First Hospital of Wenzhou Medical University, Wenzhou, China;Department of Breast Surgery, Lihuili Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China

关键词: Endocrine therapy resistance;    Hormone-dependent cancer;    Breast cancer;    Non-genomic signaling;    ER-alpha36;    Estrogen receptor;   

Others  :  822014
DOI  :  10.1186/1479-5876-12-16

 received in 2013-07-21, accepted in 2014-01-18,  发布年份 2014

【 摘 要 】

Estrogen receptor-alpha36 (ER-α36) is a new isoform of estrogen receptors without transcriptional activation domains of the classical ER-α(ER − α66). ER-α36 is mainly located in cytoplasm and plasma membrane. ER-α36 mediates non-genomic signaling and is involved in genomic signaling of other ERs. Recently ER-α36 is found to play a critical role in the development of estrogen-dependent cancers and endocrine resistance of breast cancer. The present article overviews and updates the biological nature and function of ER-α36, potential interaction of ER-α36 with other estrogen receptors and growth factor receptors, intracellular signaling pathways, potential mechanism by which ER-α36 may play an important role in the development of tumor resistance to endocrine therapies.

【 授权许可】

   
2014 Gu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Shao W, Brown M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004, 6:39-52. BioMed Central Full Text
• [2]Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962, 18:387.
• [3]Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
• [4]Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson PH: Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol 1997, 62:363-372.
• [5]Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 1996, 59:251-260.
• [6]Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005, 336:1023-1027.
• [7]Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 2006, 103:9063-9068.
• [8]Pearce ST, Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004, 50:3-22.
• [9]van der Eerden BC, Emons J, Ahmed S, Van Essen HW, Lowik CW, Wit JM, Karperien M: Evidence for genomic and nongenomic actions of estrogen in growth plate regulation in female and male rats at the onset of sexual maturation. J Endocrinol 2002, 175:277-288.
• [10]Bjornstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005, 19:833-842.
• [11]Cheskis BJ, Greger JG, Nagpal S, Freedman LP: Signaling by estrogens. J Cell Physiol 2007, 213:610-617.
• [12]Osborne CK, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622.
• [13]Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA: Update on estrogen signaling. FEBS Lett 2003, 546:17-24.
• [14]Kong EH, Pike AC, Hubbard RE: Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 2003, 31:56-59.
• [15]Hall JM, McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140:5566-5578.
• [16]Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008, 28:479-483.
• [17]Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY, Qiao J: ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol 2011, 205(227):e221-e226.
• [18]Jiang H, Teng R, Wang Q, Zhang X, Wang H, Wang Z, Cao J, Teng L: Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J Steroid Biochem Mol Biol 2008, 112:20-24.
• [19]Wang J, Li J, Fang R, Xie S, Wang L, Xu C: Expression of ERalpha36 in gastric cancer samples and their matched normal tissues. Oncol Lett 2012, 3:172-175.
• [20]Miceli V, Cocciadiferro L, Fregapane M, Zarcone M, Montalto G, Polito LM, Agostara B, Granata OM, Carruba G: Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS 2011, 15:313-317.
• [21]Chakraborty P, Roy SK: Expression of estrogen receptor alpha 36 (ESR36) in the hamster ovary throughout the estrous cycle: effects of gonadotropins. PLoS One 2013, 8:e58291.
• [22]Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M: Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 2005, 16:231-237.
• [23]Baulieu EE, Binart N, Cadepond F, Catelli MG, Chambraud B, Garnier J, Gasc JM, Groyer-Schweizer G, Oblin ME, Radanyi C, et al.: Receptor-associated nuclear proteins and steroid/antisteroid action. Ann N Y Acad Sci 1990, 595:300-315.
• [24]Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al.: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
• [25]Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994, 91:8517-8521.
• [26]Zou Y, Ding L, Coleman M, Wang Z: Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 2009, 583:1368-1374.
• [27]Kang L, Wang L, Wang ZY: Opposite regulation of estrogen receptor-alpha and its variant ER-alpha36 by the Wilms’ tumor suppressor WT1. Oncol Lett 2011, 2:337-341.
• [28]Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45:607-617.
• [29]Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P: Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
• [30]Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
• [31]Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY: Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010, 24:709-721.
• [32]Wallacides A, Chesnel A, Ajj H, Chillet M, Flament S, Dumond H: Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERalpha36 induction. Mol Cell Endocrinol 2012, 350:61-71.
• [33]Vranic S, Gatalica Z, Deng H, Frkovic-Grazio S, Lee LM, Gurjeva O, Wang ZY: ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol 2011, 64:54-57.
• [34]Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY: A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011, 30:770-780.
• [35]Zhang XT, Ding L, Kang LG, Wang ZY: Involvement of ER-alpha36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells. Oncol Rep 2012, 27:2057-2065.
• [36]Lin SL, Yan LY, Zhang XT, Yuan J, Li M, Qiao J, Wang ZY, Sun QY: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 2010, 5:e9013.
• [37]Li G, Zhang J, Jin K, He K, Zheng Y, Xu X, Wang H, Wang H, Li Z, Yu X: Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol Oncol 2013, 7:611-624.
• [38]Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, et al.: Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009, 27:3423-3429.
• [39]Kang L, Guo Y, Zhang X, Meng J, Wang ZY: A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol 2011, 127:262-268.
• [40]Dufourny B, Alblas J, Van Teeffelen HA, Van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997, 272:31163-31171.
• [41]Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, Qiao J, Schatten H, Sun QY: A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 2009, 7:102. BioMed Central Full Text
• [42]Ohshiro K, Schwartz AM, Levine PH, Kumar R: Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One 2012, 7:e30725.
• [43]McMillan J, Fatehi-Sedeh S, Sylvia VL, Bingham V, Zhong M, Boyan BD, Schwartz Z: Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta 2006, 1763:381-392.
• [44]Tong JS, Zhang QH, Wang ZB, Li S, Yang CR, Fu XQ, Hou Y, Wang ZY, Sheng J, Sun QY: ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS One 2010, 5:e15408.
• [45]Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z: Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J Biol Chem 2012, 287:7169-7181.
• [46]Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9:537-549.
• [47]Zhang J, Li G, Li Z, Yu X, Zheng Y, Jin K, Wang H, Gong Y, Sun X, Teng X, et al.: Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids 2012, 77:666-673.
• [48]Horwitz SB: Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994, 5(Suppl 6):S3-S6.
• [49]Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI: Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004, 87:167-180.
• [50]Graf GA, Matveev SV, Smart EJ: Class B scavenger receptors, caveolae and cholesterol homeostasis. Trends Cardiovasc Med 1999, 9:221-225.
• [51]Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998, 16:1391-1397.
• [52]Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 2004, 23:7893-7897.
• [53]Wang D, Huang P, Zhu B, Sun L, Huang Q, Wang J: Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines. Mol Med Rep 2012, 6:591-596.
• [54]Poola I, Koduri S, Chatra S, Clarke R: Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J Steroid Biochem Mol Biol 2000, 72:249-258.
• [55]Gotteland M, Desauty G, Delarue JC, Liu L, May E: Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol Cell Endocrinol 1995, 112:1-13.
• [56]Pfeffer U, Fecarotta E, Vidali G: Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995, 55:2158-2165.
• [57]Leygue E, Huang A, Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996, 56:4324-4327.
• [58]Pelekanou V, Notas G, Kampa M, Tsentelierou E, Radojicic J, Leclercq G, Castanas E, Stathopoulos EN: ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 2012, 77:928-934.
• [59]Zheng Y, Zhang J, Xu ZZ, Sheng JM, Zhang XC, Wang HH, Teng XD, Liu XJ, Cao J, Teng LS: Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues. J Zhejiang Univ Sci B 2010, 11:144-150.
• [60]Sun L, Wang J, Zhang L, Li X, Shen D: Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol Obstet Invest 2013, 75:68-72.
• [61]Deng H, Huang X, Fan J, Wang L, Xia Q, Yang X, Wang Z, Liu L: A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep. 2010, 24:171-6.
• [62]Zhang CC, Shapiro DJ: Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 2000, 275:479-486.
• [63]Gu Q, Korach KS, Moss RL: Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology 1999, 140:660-666.
• [64]Dutertre M, Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000, 295:431-437.
• [65]Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z, Xiao GG: let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med 2011, 17:1233-1241.
• [66]Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
• [67]Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001, 8:191-195.
• [68]Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990, 87:6883-6887.
• [69]Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 1992, 89:4037-4041.
• [70]Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS: Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 1995, 761:148-163.
• [71]Kang L, Wang ZY: Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36. J Cell Mol Med 2010, 14:1485-1493.
• [72]Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci U S A 1995, 92:4206-4210.
• [73]Pearce ST, Liu H, Jordan VC: Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 2003, 278:7630-7638.
• [74]Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757.
• [75]Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, et al.: Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat 2012, 132:843-851.
• [76]Sui M, Huang Y, Park BH, Davidson NE, Fan W: Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 2007, 67:5337-5344.
• [77]Sun L, Wang J, Zhang L, Li X, Shen D: Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol Obstet Invest 2012, 75:68-72.
• [78]Baumgartner C, Osl M, Netzer M, Baumgartner D: Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinforma 2011, 1:2. BioMed Central Full Text
• [79]Wang XD, Liotta L: Clinical bioinformatics: a new emerging science. J Clin Bioinforma 2011, 1:1. BioMed Central Full Text
• [80]Wang XD, Peer D, Petersen B: Molecular and cellular therapies: new challenges and opportunities. Mol Cell Therapies 2013, 1:1. BioMed Central Full Text
• [81]Wang XD, Marincola FM: A decade plus of translation: what do we understand? Clin Transl Med 2012, 1:3. BioMed Central Full Text
• [82]Abraham E, Marincola FM, Chen ZN, Wang XD: Clinical and translational medicine: integrative and practical science. Clin Transl Med 2012, 1:1. BioMed Central Full Text